Filtered By:
Drug: Tamoxifen
This page shows you your search results in order of date. This is page number 10.
Order by Relevance | Date
Total 2054 results found since Jan 2013.
Smarca2 genetic ablation is phenotypically benign in a safety assessment of tamoxifen-inducible conditional knockout rats
Toxicol Appl Pharmacol. 2023 Jul 13:116627. doi: 10.1016/j.taap.2023.116627. Online ahead of print.ABSTRACTSMARCA2 and SMARCA4 are the ATPases of the SWI/SNF chromatin remodeling complex, which play a significant role in regulating transcriptional activity and DNA repair in cells. SMARCA2 has become an appealing synthetic-lethal, therapeutic target in oncology, as mutational loss of SMARCA4 in many cancers leads to a functional dependency on residual SMARCA2 activity. Thus, for therapeutic development, an important step is understanding any potential safety target-associated liabilities of SMARCA2 inhibition. To best mimic...
Source: Toxicology and Applied Pharmacology - July 15, 2023 Category: Toxicology Authors: Jonathan Maher Nicola Stagg Gary Cain Roxanne Andaya Paula Katavolos Fermin Gallardo-Chang Anna Pham Xiaofen Ye Tom Januario Tuija Alcantar Roger Caothien Merone Roose-Girma Donglu Zhang Ruina Li Shu Chen Robert L Yauch Source Type: research
The immune activity of selective estrogen receptor modulators is gene and macrophage subtype-specific yet converges on Il1b downregulation
Biomed Pharmacother. 2023 Jul 11;165:115008. doi: 10.1016/j.biopha.2023.115008. Online ahead of print.ABSTRACTRaloxifene belongs to the family of Selective Estrogen Receptor Modulators (SERMs), which are drugs widely prescribed for Estrogen Receptor alpha (ERα)-related pathologies. Recently, SERMs are being tested in repurposing strategies for ERα-independent clinical indications, including a wide range of microbial infections. Macrophages are central in the fight against pathogen invasion. Despite estrogens have been shown to regulate macrophage phenotype, SERMs activity in these cells is still poorly defined. We invest...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - July 13, 2023 Category: Drugs & Pharmacology Authors: Chiara Sfogliarini Giovanna Pepe Candida Maria Cesta Marcello Allegretti Massimo Locati Elisabetta Vegeto Source Type: research
Managing Menopausal Symptoms: Common Questions and Answers
Am Fam Physician. 2023 Jul;108(1):28-39.ABSTRACTMenopausal symptoms are widespread and significantly impact quality of life. Common symptoms of menopause are vasomotor (i.e., hot flashes and night sweats) and genitourinary (e.g., vulvovaginal irritation and dryness, dyspareunia, urinary problems), although women may also experience changes in sexual function, mood, and sleep. Estrogen-containing hormone therapy is effective treatment for vasomotor symptoms. Nonhormonal medications for vasomotor symptoms include selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and gabapentin. Selective ...
Source: American Family Physician - July 13, 2023 Category: Primary Care Authors: Jennifer G Chang Meghan N Lewis Maggie C Wertz Source Type: research
The immune activity of selective estrogen receptor modulators is gene and macrophage subtype-specific yet converges on Il1b downregulation
Biomed Pharmacother. 2023 Jul 11;165:115008. doi: 10.1016/j.biopha.2023.115008. Online ahead of print.ABSTRACTRaloxifene belongs to the family of Selective Estrogen Receptor Modulators (SERMs), which are drugs widely prescribed for Estrogen Receptor alpha (ERα)-related pathologies. Recently, SERMs are being tested in repurposing strategies for ERα-independent clinical indications, including a wide range of microbial infections. Macrophages are central in the fight against pathogen invasion. Despite estrogens have been shown to regulate macrophage phenotype, SERMs activity in these cells is still poorly defined. We invest...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - July 13, 2023 Category: Drugs & Pharmacology Authors: Chiara Sfogliarini Giovanna Pepe Candida Maria Cesta Marcello Allegretti Massimo Locati Elisabetta Vegeto Source Type: research
Managing Menopausal Symptoms: Common Questions and Answers
Am Fam Physician. 2023 Jul;108(1):28-39.ABSTRACTMenopausal symptoms are widespread and significantly impact quality of life. Common symptoms of menopause are vasomotor (i.e., hot flashes and night sweats) and genitourinary (e.g., vulvovaginal irritation and dryness, dyspareunia, urinary problems), although women may also experience changes in sexual function, mood, and sleep. Estrogen-containing hormone therapy is effective treatment for vasomotor symptoms. Nonhormonal medications for vasomotor symptoms include selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and gabapentin. Selective ...
Source: American Family Physician - July 13, 2023 Category: Primary Care Authors: Jennifer G Chang Meghan N Lewis Maggie C Wertz Source Type: research
EZH2 Expression and Survival for ER+/tamoxifen Treated Breast Cancer Patients with rs2302427 C & gt;G: A Novel Prognostic and Risk Predictive Biomarker
CONCLUSIONS: Three significant findings of the SNP rs.2302427C>G (Asp193His) i.e., protective role against breast cancer, survival advantage in ER+/tamoxifen treated breast cancer patients, and decreased expression due to the presence of mutant GG genotype, suggests considering it as an important prognostic biomarker for a good survival outcome of breast cancer patients treated with ER+/tamoxifen. Compared with other studies, the other SNP rs.3757441T>C was observed to have a protective effect in breast cancer biology but plays an antagonistic role in colorectal cancer (CRC) biology. To our knowledge, this is the fir...
Source: Cell Research - July 12, 2023 Category: Cytology Authors: Nisha Gautam Satbir Kaur Surender Kashyap Source Type: research
RNA interference or small molecule inhibition of Runx1 in the border zone prevents cardiac contractile dysfunction following myocardial infarction
CONCLUSIONS: Our results confirm the translational potential of RUNX1 as a novel therapeutic target in myocardial infarction, with wider opportunities for use across a range of cardiac diseases where RUNX1 drives adverse cardiac remodelling.PMID:37433039 | DOI:10.1093/cvr/cvad107
Source: Cell Research - July 11, 2023 Category: Cytology Authors: Tamara P Martin Eilidh A MacDonald Ashley Bradley Holly Watson Priyanka Saxena Eva A Rog-Zielinska Anmar Raheem Simon Fisher Ali Ali Mohamed Elbassioni Ohood Almuzaini Catriona Booth Morna Campbell Alex Riddell Pawel Herzyk Karen Blyth Colin Nixon Lorena Source Type: research
Suppression of breast cancer: modulation of estrogen receptor and downregulation of gene expression using natural products
Nat Prod Res. 2023 Jul 10:1-10. doi: 10.1080/14786419.2023.2232926. Online ahead of print.ABSTRACTThe main cause of cancer death among women is breast cancer. The most common type of breast cancer is the estrogen receptor positive breast cancer. Discovery of estrogen receptor provided a highly effective target for treatment of hormone-dependent breast cancer. Selective estrogen receptor inhibitors are useful for halting the growth of breast cancer cells and inducing apoptosis. Tamoxifen, a popular selective estrogen receptor modulator, can treat breast cancer but also has unfavourable side effects due to its estrogenic act...
Source: Cell Research - July 10, 2023 Category: Cytology Authors: Haidy Ahmed Alyaa Abdelraheem Mona Salem Martha Sabry Nada Fekry Fatma Mohamed Ahmed Saber Diletta Piatti Miral Sabry Omar Sabry Giovanni Caprioli Source Type: research
The beneficial effects of tamoxifen on arteries: a key player for cardiovascular health of breast cancer patient
Biochem Pharmacol. 2023 Jul 5:115677. doi: 10.1016/j.bcp.2023.115677. Online ahead of print.ABSTRACTBreast cancer is the most common cancer in women. Over the past few decades, advances in cancer detection and treatment have significantly improved survival rate of breast cancer patients. However, due to the cardiovascular toxicity of cancer treatments (chemotherapy, anti-HER2 antibodies and radiotherapy), cardiovascular diseases (CVD) have become an increasingly important cause of long-term morbidity and mortality in breast cancer survivors. Endocrine therapies are prescribed to reduce the risk of recurrence and specific d...
Source: Biochemical Pharmacology - July 7, 2023 Category: Drugs & Pharmacology Authors: Morgane Davezac Cecile Meneur Melissa Buscato Rana Zahreddine Jean-Fran çois Arnal Florence Dalenc Fran çoise Lenfant Coralie Fontaine Source Type: research
The beneficial effects of tamoxifen on arteries: A key player for cardiovascular health of breast cancer patient
Biochem Pharmacol. 2023 Jul 5;214:115677. doi: 10.1016/j.bcp.2023.115677. Online ahead of print.ABSTRACTBreast cancer is the most common cancer in women. Over the past few decades, advances in cancer detection and treatment have significantly improved survival rate of breast cancer patients. However, due to the cardiovascular toxicity of cancer treatments (chemotherapy, anti-HER2 antibodies and radiotherapy), cardiovascular diseases (CVD) have become an increasingly important cause of long-term morbidity and mortality in breast cancer survivors. Endocrine therapies are prescribed to reduce the risk of recurrence and specif...
Source: Biochemical Pharmacology - July 7, 2023 Category: Drugs & Pharmacology Authors: Morgane Davezac Cecile Meneur Melissa Buscato Rana Zahreddine Jean-Fran çois Arnal Florence Dalenc Fran çoise Lenfant Coralie Fontaine Source Type: research
